Immutep AIPAC Phase IIb Eftilagimod Alpha Breast Cancer Biomarker Results

Phase IIb clinical trial results from the AIPAC study evaluating eftilagimod alpha, a soluble LAG-3 protein immunotherapy, combined with paclitaxel in hormone receptor-positive HER2-negative metastatic breast cancer. Biomarker analyses demonstrate significant increases in circulating monocytes, CD8+ T cells, and CXCL10 in the eftilagimod arm compared to placebo, with on-treatment increases linked to improved overall survival. Subgroup analyses identified patient populations showing clinically meaningful improvements in progression-free survival, overall response rate, and overall survival with the combination therapy.